Further research into phosphoinositides, which are essential for many biological and pathological processes, has enabled the detection of tiny but significant changes in intracellular phosphoinositide levels. PRMC-MS is now able to entail the development of novel therapies for cancer and other diseases.
In addition, the use of PRMC-MS to assess phosphoinositide signatures at the acyl variant level in tissue and liquid biopsies may reveal biomarkers suitable for a wide variety of clinical applications.
Applications such as the above may be beneficial in the future, particularly when it comes to the creation of a therapeutic agent that identifies a specific pathogenic phosphoinositide acyl variant, and thus opens the way for more precise therapeutic methods and therapies for patients with severe illnesses.
